Subpial transection surgery for XXXX .

@entity1 @entity410 @entity302
BACKGROUND: Nearly 30% of @entity1 with @entity302 continue to have @entity410 in spite of using several antiepileptic drug (AED) regimens. Such @entity1 are regarded as having refractory, or uncontrolled, @entity302 . No definition of uncontrolled, or medically refractory, @entity302 has been universally accepted, but for the purposes of this review, we will consider @entity410 as drug resistant if they have failed to respond to a minimum of two AEDs. It is believed that early surgical intervention may prevent @entity410 at a younger age, which, in turn, may improve the intellectual and social status of @entity1 . Many types of surgery are available for treatment of @entity302 ; one such procedure is known as subpial transection. OBJECTIVES: To determine the benefits and adverse effects of subpial transection for partial-onset @entity410 and generalised @entity410 in @entity1 and adults. SEARCH METHODS: We searched the Cochrane Epilepsy Group Specialised Register (29 June 2015), the Cochrane Central Register of Controlled Trials (CENTRAL; May 2015, Issue 5) and MEDLINE (1946 to 29 June 2015). We imposed no language restrictions. SELECTION CRITERIA: We considered all randomised and quasi-randomised parallel-group studies, whether blinded or non-blinded. DATA COLLECTION AND ANALYSIS: Two review authors (BK and SR) independently screened trials identified by the search. The same two review authors planned to independently assess the methodological quality of studies. When studies were identified for inclusion, one review author would have extracted the data, and the other would have verified the data. MAIN RESULTS: We found no relevant studies. AUTHORS' CONCLUSIONS: We found no evidence to support or refute use of subpial transection surgery for @entity1 with medically @entity302 . Well-designed randomised controlled trials are needed to guide clinical practice.
